 "Covid-19 coronavirus")
No matter how keen the Russian Direct Investment Fund (RDIF) is on bringing its Sputnik V to the Indian soil, the sovereign wealth fund’s distribution partner in India — Dr Reddy’s Laboratories (DRL) — is yet to file a formal application to start Phase 3 clinical trials (part of a multi-centre bridge trial of Sputnik V over 1,000 volunteers) here, said sources at the Central Drugs and Standards Control Organisation.
Sources further added that there were no plans for any emergency-use authorisation of the Sputnik V without relevant and convincing local data.
An email sent to DRL remained unanswered till
